Charlotte Skoglund
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Charlotte Skoglund has a total of 76 co-authors. Here are the top co-authors by number of shared publications:
Henrik Larsson
Department of Medical Epidemiology and Biostatistics Karolinska Institutet Stockholm Sweden
5 shared publications- Helena Kopp Kallner
Department of Clinical Sciences at Danderyd Hospital, Karolinska Institutet
3 shared publications - Ralf Kuja-Halkola
Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden
3 shared publications - Anna Löf Granström
Department of Clinical Sciences, Danderyd Hospital, Karolinska Institutet, Stockholm, Sweden
2 shared publications Anna Wikman
Uppsala University, Uppsala, Sweden
2 shared publications- Anna Wikman
Department of Women’s and Children’s Health, Uppsala University, Uppsala, Sweden
2 shared publications
Latest Publications
- Open Access
- 10 April 2026
- Published by Taylor & Francis in Nordic Journal of Psychiatry
- Vol. 80 (4) , 219-225
Sex and age trends in ADHD medication use in Norway, 2020–2022: a nationwide register study
Attention-deficit/hyperactivity disorder (ADHD) is a common neurodevelopmental condition across the lifespan. Early epidemiological surveys established adult ADHD as prevalent across countries [1,2...
- 10 April 2026
- Published by Taylor & Francis in Nordic Journal of Psychiatry
- Vol. 80 (4) , 219-225
Open AccessSex and age trends in ADHD medication use in Norway, 2020–2022: a nationwide register study
Attention-deficit/hyperactivity disorder (ADHD) is a common neurodevelopmental condition across the lifespan. Early epidemiological surveys established adult ADHD as prevalent across countries [1,2...
- Open Access
- 15 March 2024
- Published by Springer Nature in CNS Drugs
- Vol. 38 (4) , 303-314
Attention-Deficit Hyperactivity Disorder (ADHD) Medication Use Trajectories Among Women in the Perinatal Period
Background An increasing number of women of reproductive age are treated with attention-deficit hyperactivity disorder (ADHD) medication; however, patterns of ADHD medication use for women in the perinatal period have not been well described. Objective This study aimed to describe ADHD medication use patterns from 1 year before pregnancy to 1 year after delivery, and to describe sociodemographic characteristics and clinical features by medication trajectories. Methods The population-based cohort study included pregnancies in Denmark between 1997 and 2020, from the Medical Birth Register, by women who filled at least one prescription for ADHD medication from 12 months before pregnancy until 12 months after delivery. We applied group-based trajectory modeling to classify women into subgroups based on the identification of heterogeneous ADHD medication treatment patterns, and described the characteristics associated with these groups. Results Overall, we included 4717 pregnancies leading to liveborn singletons by 4052 mothers with a mean (standard deviation) age of 27.5 (5.6) years. We identified four treatment trajectories across pregnancy and the postpartum period: continuers (23.3%), discontinuers (41.8%), interrupters who ceased filling prescriptions during pregnancy but resumed postpartum (17.2%), and postpartum initiators (17.7%). Continuers were older at the time of conception, gave birth in more recent years, were more likely to smoke during pregnancy, and used other psychotropic medications during pregnancy. A large proportion of continuers used methylphenidate (89.1%) compared with the other groups (75.9–84.1%) and had switched ADHD medication type during the whole period (16.4% vs. 7.4–14.8%). Conclusion We found that approximately 60% of women discontinued or interrupted their ADHD medication around pregnancy, and those who continued differed in sociodemographic and clinical factors that may reflect more severe ADHD.
- 15 March 2024
- Published by Springer Nature in CNS Drugs
- Vol. 38 (4) , 303-314
Open AccessAttention-Deficit Hyperactivity Disorder (ADHD) Medication Use Trajectories Among Women in the Perinatal Period
Background An increasing number of women of reproductive age are treated with attention-deficit hyperactivity disorder (ADHD) medication; however, patterns of ADHD medication use for women in the perinatal period have not been well described. Objective This study aimed to describe ADHD medication use patterns from 1 year before pregnancy to 1 year after delivery, and to describe sociodemographic characteristics and clinical features by medication trajectories. Methods The population-based cohort study included pregnancies in Denmark between 1997 and 2020, from the Medical Birth Register, by women who filled at least one prescription for ADHD medication from 12 months before pregnancy until 12 months after delivery. We applied group-based trajectory modeling to classify women into subgroups based on the identification of heterogeneous ADHD medication treatment patterns, and described the characteristics associated with these groups. Results Overall, we included 4717 pregnancies leading to liveborn singletons by 4052 mothers with a mean (standard deviation) age of 27.5 (5.6) years. We identified four treatment trajectories across pregnancy and the postpartum period: continuers (23.3%), discontinuers (41.8%), interrupters who ceased filling prescriptions during pregnancy but resumed postpartum (17.2%), and postpartum initiators (17.7%). Continuers were older at the time of conception, gave birth in more recent years, were more likely to smoke during pregnancy, and used other psychotropic medications during pregnancy. A large proportion of continuers used methylphenidate (89.1%) compared with the other groups (75.9–84.1%) and had switched ADHD medication type during the whole period (16.4% vs. 7.4–14.8%). Conclusion We found that approximately 60% of women discontinued or interrupted their ADHD medication around pregnancy, and those who continued differed in sociodemographic and clinical factors that may reflect more severe ADHD.
- Open Access
- 28 November 2023
- Published by Wiley in Journal of Child Psychology and Psychiatry
- Vol. 65 (6) , 832-844
Time after time: failure to identify and support females with ADHD – a Swedish population register study
Background: Attention deficit hyperactivity disorder (ADHD) is associated with risk taking and negative health‐related outcomes across the lifespan. Due to delay in referral and diagnostics, young females with ADHD may not be identified, nor appropriately supported by adequate interventions. Methods: A total of 85,330 individuals with ADHD, all of whom were residents in Stockholm County between January 01, 2011, and December 31, 2021, were included as participants in this population‐based, cross‐sectional cohort study. Population controls ( n = 426,626) were matched by age, sex, and socioeconomic status (SES). Data was obtained from Regional Healthcare Data Warehouse of Region Stockholm (VAL) in Stockholm County. Exposure was ADHD‐index, defined as the first record of either ICD‐10 F90 diagnosis and/or ATC‐code for stimulant or non‐stimulant ADHD‐medication during the study period. Primary outcome was age at ADHD‐index. Secondary outcome measures were psychiatric comorbidity, pharmacological treatment, and health care utilization, prior to and after ADHD‐index. Results: Females were older at ADHD‐index (23.5 years, SD 13.8) compared to males (19.6 years, SD 13.9, 95% CI of difference 3.74–4.11). Overall, females with ADHD showed higher rates of psychiatric comorbidity, pharmacological treatment, and health care utilization, compared to males with ADHD and female controls. Conclusions: Females with ADHD receive diagnosis and treatment for ADHD approximately 4 years later than males. They have a higher burden of comorbid psychiatric conditions and health care utilization, compared to males with ADHD and female controls, both prior to and after ADHD‐index. To prevent long‐term adverse consequences for females with ADHD, methods, and tools for early diagnosis and treatments that mitigate personal suffering and societal burden are warranted.
- 28 November 2023
- Published by Wiley in Journal of Child Psychology and Psychiatry
- Vol. 65 (6) , 832-844
Open AccessTime after time: failure to identify and support females with ADHD – a Swedish population register study
Background: Attention deficit hyperactivity disorder (ADHD) is associated with risk taking and negative health‐related outcomes across the lifespan. Due to delay in referral and diagnostics, young females with ADHD may not be identified, nor appropriately supported by adequate interventions. Methods: A total of 85,330 individuals with ADHD, all of whom were residents in Stockholm County between January 01, 2011, and December 31, 2021, were included as participants in this population‐based, cross‐sectional cohort study. Population controls ( n = 426,626) were matched by age, sex, and socioeconomic status (SES). Data was obtained from Regional Healthcare Data Warehouse of Region Stockholm (VAL) in Stockholm County. Exposure was ADHD‐index, defined as the first record of either ICD‐10 F90 diagnosis and/or ATC‐code for stimulant or non‐stimulant ADHD‐medication during the study period. Primary outcome was age at ADHD‐index. Secondary outcome measures were psychiatric comorbidity, pharmacological treatment, and health care utilization, prior to and after ADHD‐index. Results: Females were older at ADHD‐index (23.5 years, SD 13.8) compared to males (19.6 years, SD 13.9, 95% CI of difference 3.74–4.11). Overall, females with ADHD showed higher rates of psychiatric comorbidity, pharmacological treatment, and health care utilization, compared to males with ADHD and female controls. Conclusions: Females with ADHD receive diagnosis and treatment for ADHD approximately 4 years later than males. They have a higher burden of comorbid psychiatric conditions and health care utilization, compared to males with ADHD and female controls, both prior to and after ADHD‐index. To prevent long‐term adverse consequences for females with ADHD, methods, and tools for early diagnosis and treatments that mitigate personal suffering and societal burden are warranted.
- Open Access
- 1 November 2022
- Published by Elsevier in Journal of the American Academy of Child & Adolescent Psychiatry
- Vol. 62 (6) , 665-674
Hormonal Contraceptive Use and Risk of Depression Among Young Women With Attention-Deficit/Hyperactivity Disorder
- 1 November 2022
- Published by Elsevier in Journal of the American Academy of Child & Adolescent Psychiatry
- Vol. 62 (6) , 665-674
Open AccessHormonal Contraceptive Use and Risk of Depression Among Young Women With Attention-Deficit/Hyperactivity Disorder
- Open Access
- 15 April 2022
- Published by Springer Nature in Journal of Medical Case Reports
- Vol. 16 (1) , 1-6
The partial µ-opioid agonist buprenorphine in autism spectrum disorder: a case report
Background: There are currently no approved medications for impaired social cognition and function, core symptoms of autism spectrum disorder. We describe marked improvement of these symptoms with long-term low-dose administration of the partial µ-opioid agonist buprenorphine. We discuss these observations in the context of a role for endogenous opioid systems in social attachment, and theories integrating those findings mechanistically with autism spectrum disorder. Case presentation: M, a 43-year-old Caucasian male, is medically healthy. Despite social difficulties since childhood, he completed high school with better-than-average grades, but failed university education. A psychiatric evaluation in his twenties diagnosed attention deficit hyperactivity disorder but also noted symptoms of coexisting autism spectrum disorder. M accidentally came across buprenorphine in his late twenties and experienced progressively improved social functioning on a low daily dosage (0.5–1.0 mg/day), an effect maintained for 15 years. He lived independently and maintained a part-time occupation. After abrupt discontinuation of treatment, his autistic symptoms returned, and function deteriorated. Following evaluation by our team, buprenorphine was resumed, with gradual return to prior level of functioning. An attempt to formally evaluate M both on and off medication was agreed with him and approved by the Swedish Ethics Authority, but medication had to be resumed when the patient worsened following discontinuation. Conclusions: According to the µ-opioid receptor balance model, both excessive and deficient μ-receptor activity may negatively influence social behavior, and accordingly both opioid agonist and opioid antagonist treatment may be able to improve social functioning, depending on an individual’s opioid tone before treatment. Our case report is consistent with these hypotheses, and given the extensive unmet medical needs in individuals with autism spectrum disorders, randomized controlled trial appears warranted.
- 15 April 2022
- Published by Springer Nature in Journal of Medical Case Reports
- Vol. 16 (1) , 1-6
Open AccessThe partial µ-opioid agonist buprenorphine in autism spectrum disorder: a case report
Background: There are currently no approved medications for impaired social cognition and function, core symptoms of autism spectrum disorder. We describe marked improvement of these symptoms with long-term low-dose administration of the partial µ-opioid agonist buprenorphine. We discuss these observations in the context of a role for endogenous opioid systems in social attachment, and theories integrating those findings mechanistically with autism spectrum disorder. Case presentation: M, a 43-year-old Caucasian male, is medically healthy. Despite social difficulties since childhood, he completed high school with better-than-average grades, but failed university education. A psychiatric evaluation in his twenties diagnosed attention deficit hyperactivity disorder but also noted symptoms of coexisting autism spectrum disorder. M accidentally came across buprenorphine in his late twenties and experienced progressively improved social functioning on a low daily dosage (0.5–1.0 mg/day), an effect maintained for 15 years. He lived independently and maintained a part-time occupation. After abrupt discontinuation of treatment, his autistic symptoms returned, and function deteriorated. Following evaluation by our team, buprenorphine was resumed, with gradual return to prior level of functioning. An attempt to formally evaluate M both on and off medication was agreed with him and approved by the Swedish Ethics Authority, but medication had to be resumed when the patient worsened following discontinuation. Conclusions: According to the µ-opioid receptor balance model, both excessive and deficient μ-receptor activity may negatively influence social behavior, and accordingly both opioid agonist and opioid antagonist treatment may be able to improve social functioning, depending on an individual’s opioid tone before treatment. Our case report is consistent with these hypotheses, and given the extensive unmet medical needs in individuals with autism spectrum disorders, randomized controlled trial appears warranted.
- Open Access
- 10 November 2021
- Published by Wiley in Acta Obstetricia et Gynecologica Scandinavica
- Vol. 101 (1) , 77-83
Provision of long‐acting reversible contraception at surgical abortion—A cross‐sectional nationwide register study
Introduction: Provision of long‐acting reversible contraception (LARC) at surgical abortion is safe, practical, and leads to higher user rates than does delayed provision. The aim of this study was to explore whether provision of LARC at surgical abortion is associated with known risk factors for subsequent abortions and inconsistent use of contraception, including sociodemographic factors and psychiatric disorders.Material and Methods: This was a register‐based cross‐sectional study of 6251 women having a surgical abortion in Sweden. Data were collected from National health and population registers. Women with procedure codes for surgical abortion were identified in the National Patient Register from October 2016 to December 2018. Information from Statistics Sweden, the National Patient Register, and the Swedish prescribed drug register on sociodemographic factors, psychiatric disorders, and dispensed LARC was added and linked on an individual level. Associations of sociodemographic factors and psychiatric disorders with LARC provision were explored with generalized logit mixed models and presented as crude and adjusted odds ratios with 95% confidence intervals (CIs).Results: The overall rate of LARC provision at the time of the abortion was 2515/6251 (40.2%). Younger age and lower level of education were associated with an increased likelihood of LARC provision. In the study population, 2624/6251 (42.0%) patients had a pre‐ or post‐abortion psychiatric disorder, a factor associated with an increased likelihood of LARC provision compared with women with no such disorders (adjusted odds ratio 1.21; 95% CI 1.08–1.34). The highest rates and odds were seen among women with personality, substance use, and/or neurodevelopmental disorders and among women with multiple psychiatric disorders.Conclusions: Sociodemographic risk factors and psychiatric disorders were associated with increased LARC provision at surgical abortion, indicating that women at high risk of unwanted pregnancies are provided with effective contraception. Still, less than half of all women undergoing surgical abortion were provided with LARC, suggesting that contraceptive access and counseling prior to a surgical abortion can be improved.
- 10 November 2021
- Published by Wiley in Acta Obstetricia et Gynecologica Scandinavica
- Vol. 101 (1) , 77-83
Open AccessProvision of long‐acting reversible contraception at surgical abortion—A cross‐sectional nationwide register study
Introduction: Provision of long‐acting reversible contraception (LARC) at surgical abortion is safe, practical, and leads to higher user rates than does delayed provision. The aim of this study was to explore whether provision of LARC at surgical abortion is associated with known risk factors for subsequent abortions and inconsistent use of contraception, including sociodemographic factors and psychiatric disorders.Material and Methods: This was a register‐based cross‐sectional study of 6251 women having a surgical abortion in Sweden. Data were collected from National health and population registers. Women with procedure codes for surgical abortion were identified in the National Patient Register from October 2016 to December 2018. Information from Statistics Sweden, the National Patient Register, and the Swedish prescribed drug register on sociodemographic factors, psychiatric disorders, and dispensed LARC was added and linked on an individual level. Associations of sociodemographic factors and psychiatric disorders with LARC provision were explored with generalized logit mixed models and presented as crude and adjusted odds ratios with 95% confidence intervals (CIs).Results: The overall rate of LARC provision at the time of the abortion was 2515/6251 (40.2%). Younger age and lower level of education were associated with an increased likelihood of LARC provision. In the study population, 2624/6251 (42.0%) patients had a pre‐ or post‐abortion psychiatric disorder, a factor associated with an increased likelihood of LARC provision compared with women with no such disorders (adjusted odds ratio 1.21; 95% CI 1.08–1.34). The highest rates and odds were seen among women with personality, substance use, and/or neurodevelopmental disorders and among women with multiple psychiatric disorders.Conclusions: Sociodemographic risk factors and psychiatric disorders were associated with increased LARC provision at surgical abortion, indicating that women at high risk of unwanted pregnancies are provided with effective contraception. Still, less than half of all women undergoing surgical abortion were provided with LARC, suggesting that contraceptive access and counseling prior to a surgical abortion can be improved.
- Open Access
- 14 June 2020
- Published by Wiley in International Journal of Cancer
- Vol. 147 (12) , 3349-3360
Increased risk of mental health problems after cancer during adolescence: A register‐based cohort study
In this nationwide, register‐based study, we estimated the risk of mental health problems in 2822 individuals diagnosed with cancer in adolescence (13‐19 years). Mental health problems were assessed by psychiatric diagnoses and/or prescribed psychotropic drugs. Cox proportional hazards models estimated hazard ratio (HR) for a psychiatric diagnosis and prescription of psychotropic drug compared to a matched comparison group (n = 28 220). Estimates were adjusted for calendar period and parent characteristics (eg, history of psychiatric diagnosis, education, country of birth). We found an increased risk of a psychiatric diagnosis during the first 5 years after the cancer diagnosis (females: HR 1.23, 95% CI, 1.06‐1.44; males: HR 1.32, 95% CI, 1.11‐1.56), and at >5 years after diagnosis (females: HR 1.31, 95% CI, 1.09‐1.58, males: HR 1.45, 95% CI, 1.18‐1.77). The risk of being prescribed antidepressant (females: HR 1.54, 95% CI, 1.30‐1.84, males: HR 2.06, 95% CI, 1.66‐2.55), antipsychotic (females: HR 2.28, 95% CI, 1.56‐3.34, males: HR 3.07, 95% CI, 2.13‐4.42), anxiolytic (females: HR 1.95, 95% CI, 1.64‐2.31, males: HR 4.02, 95% CI, 3.34‐4.84) and sedative drugs (females: HR 2.24, 95% CI, 1.84‐2.72, males: HR 3.91, 95% CI, 3.23‐4.73) were higher than for comparisons during the first 5 years after diagnosis. Median age at first psychiatric diagnosis and first prescribed psychotropic drug were 18 years. In conclusion, cancer during adolescence is associated with increased risk of mental health problems that may develop in close proximity to treatment. The findings emphasize the need for comprehensive care during treatment and follow‐up.
- 14 June 2020
- Published by Wiley in International Journal of Cancer
- Vol. 147 (12) , 3349-3360
Open AccessIncreased risk of mental health problems after cancer during adolescence: A register‐based cohort study
In this nationwide, register‐based study, we estimated the risk of mental health problems in 2822 individuals diagnosed with cancer in adolescence (13‐19 years). Mental health problems were assessed by psychiatric diagnoses and/or prescribed psychotropic drugs. Cox proportional hazards models estimated hazard ratio (HR) for a psychiatric diagnosis and prescription of psychotropic drug compared to a matched comparison group (n = 28 220). Estimates were adjusted for calendar period and parent characteristics (eg, history of psychiatric diagnosis, education, country of birth). We found an increased risk of a psychiatric diagnosis during the first 5 years after the cancer diagnosis (females: HR 1.23, 95% CI, 1.06‐1.44; males: HR 1.32, 95% CI, 1.11‐1.56), and at >5 years after diagnosis (females: HR 1.31, 95% CI, 1.09‐1.58, males: HR 1.45, 95% CI, 1.18‐1.77). The risk of being prescribed antidepressant (females: HR 1.54, 95% CI, 1.30‐1.84, males: HR 2.06, 95% CI, 1.66‐2.55), antipsychotic (females: HR 2.28, 95% CI, 1.56‐3.34, males: HR 3.07, 95% CI, 2.13‐4.42), anxiolytic (females: HR 1.95, 95% CI, 1.64‐2.31, males: HR 4.02, 95% CI, 3.34‐4.84) and sedative drugs (females: HR 2.24, 95% CI, 1.84‐2.72, males: HR 3.91, 95% CI, 3.23‐4.73) were higher than for comparisons during the first 5 years after diagnosis. Median age at first psychiatric diagnosis and first prescribed psychotropic drug were 18 years. In conclusion, cancer during adolescence is associated with increased risk of mental health problems that may develop in close proximity to treatment. The findings emphasize the need for comprehensive care during treatment and follow‐up.
- 18 October 2019
- Published by Wiley in Journal of Child Psychology and Psychiatry
- Vol. 61 (2) , 140-147
Use of medication for attention‐deficit/hyperactivity disorder and risk of unintentional injuries in children and adolescents with co‐occurring neurodevelopmental disorders
Background: Attention‐deficit/hyperactivity disorder ( ADHD ) is often associated with other neurodevelopmental disorders ( ND s) and with risky behaviors and adverse health outcomes, including injuries. Treatment with ADHD medication has been associated with reduced risk of injuries. However, it is unknown whether the association is present in individuals with co‐occurring ND s. The aim of the present study was to estimate the association between ADHD medication use and unintentional injuries in Sweden in children and adolescents with ADHD , including those with co‐occurring ND s. Methods: Using a linkage of several national registers via the unique personal identification number, we identified individuals with a diagnosis of ADHD and of other ND s, including autism spectrum disorder, intellectual disability, communication disorders, learning disorders and motor disorders. The primary outcome was unintentional injuries. Secondary outcome was traumatic brain injury ( TBI ). Individuals were followed from January 1st 2006 or their 5th birthday or the date of the first unintentional injury, whichever came last, to December 31st 2013 or their 18th birthday or death, whichever came first. We compared the rate of injuries during periods on‐treatment with the rate of injuries during periods off‐treatment within the same individual using stratified Cox regression to calculate hazard ratio ( HR ) with 95% confidence intervals ( CI s). Results: For children and adolescents with ADHD ( N = 9,421) the rate of any unintentional injuries ( HR = 0.85; 95% CI = 0.78–0.92) and TBI s ( HR = 0.27; 95% CI s = 0.20–0.38) during medicated periods was lower than during non‐medicated periods. Similar results were found among individuals with co‐occurring ND s ( N = 2,986), for unintentional injuries ( HR = 0.88; 95% CI = 0.77–1.01) and for TBI s ( HR = 0.27; 95% CI = 0.16–0.44). Conclusions: Beneficial effects of ADHD medication may extend beyond reduction of ADHD core symptoms to prevention of unintentional injuries in children and adolescents, including individuals with co‐occurring ND s.
- 18 October 2019
- Published by Wiley in Journal of Child Psychology and Psychiatry
- Vol. 61 (2) , 140-147
Use of medication for attention‐deficit/hyperactivity disorder and risk of unintentional injuries in children and adolescents with co‐occurring neurodevelopmental disorders
Background: Attention‐deficit/hyperactivity disorder ( ADHD ) is often associated with other neurodevelopmental disorders ( ND s) and with risky behaviors and adverse health outcomes, including injuries. Treatment with ADHD medication has been associated with reduced risk of injuries. However, it is unknown whether the association is present in individuals with co‐occurring ND s. The aim of the present study was to estimate the association between ADHD medication use and unintentional injuries in Sweden in children and adolescents with ADHD , including those with co‐occurring ND s. Methods: Using a linkage of several national registers via the unique personal identification number, we identified individuals with a diagnosis of ADHD and of other ND s, including autism spectrum disorder, intellectual disability, communication disorders, learning disorders and motor disorders. The primary outcome was unintentional injuries. Secondary outcome was traumatic brain injury ( TBI ). Individuals were followed from January 1st 2006 or their 5th birthday or the date of the first unintentional injury, whichever came last, to December 31st 2013 or their 18th birthday or death, whichever came first. We compared the rate of injuries during periods on‐treatment with the rate of injuries during periods off‐treatment within the same individual using stratified Cox regression to calculate hazard ratio ( HR ) with 95% confidence intervals ( CI s). Results: For children and adolescents with ADHD ( N = 9,421) the rate of any unintentional injuries ( HR = 0.85; 95% CI = 0.78–0.92) and TBI s ( HR = 0.27; 95% CI s = 0.20–0.38) during medicated periods was lower than during non‐medicated periods. Similar results were found among individuals with co‐occurring ND s ( N = 2,986), for unintentional injuries ( HR = 0.88; 95% CI = 0.77–1.01) and for TBI s ( HR = 0.27; 95% CI = 0.16–0.44). Conclusions: Beneficial effects of ADHD medication may extend beyond reduction of ADHD core symptoms to prevention of unintentional injuries in children and adolescents, including individuals with co‐occurring ND s.
- Open Access
- 2 October 2019
- Published by American Medical Association (AMA) in JAMA Network Open
- Vol. 2 (10) , e1912463
Association of Attention-Deficit/Hyperactivity Disorder With Teenage Birth Among Women and Girls in Sweden
Attention-deficit/hyperactivity disorder (ADHD) is a prevalent neurodevelopmental disorder characterized by symptoms of hyperactivity, impulsivity, and inattention, and it is associated with a plethora of adverse health outcomes throughout life.1,2 The worldwide prevalence of childhood and adolescent ADHD is estimated to be approximately 5%.3,4 Importantly, children with ADHD have 2-fold the likelihood of mortality, 2-fold again among individuals whose symptoms persist into adulthood, which is associated with a significantly reduced estimated life expectancy.5,6
- 2 October 2019
- Published by American Medical Association (AMA) in JAMA Network Open
- Vol. 2 (10) , e1912463
Open AccessAssociation of Attention-Deficit/Hyperactivity Disorder With Teenage Birth Among Women and Girls in Sweden
Attention-deficit/hyperactivity disorder (ADHD) is a prevalent neurodevelopmental disorder characterized by symptoms of hyperactivity, impulsivity, and inattention, and it is associated with a plethora of adverse health outcomes throughout life.1,2 The worldwide prevalence of childhood and adolescent ADHD is estimated to be approximately 5%.3,4 Importantly, children with ADHD have 2-fold the likelihood of mortality, 2-fold again among individuals whose symptoms persist into adulthood, which is associated with a significantly reduced estimated life expectancy.5,6
- 1 October 2019
- Published by Elsevier in Journal of Pediatric Surgery
- Vol. 54 (10) , 2024-2027
No increased risk of attention deficit hyperactivity disorders in patients with Hirschsprung disease
- 1 October 2019
- Published by Elsevier in Journal of Pediatric Surgery
- Vol. 54 (10) , 2024-2027
No increased risk of attention deficit hyperactivity disorders in patients with Hirschsprung disease